

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

---

**Form 8-K**

---

**CURRENT REPORT**

Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 5, 2015

---

**Dynavax Technologies Corporation**

(Exact name of registrant as specified in its charter)

---

Commission File Number: 001-34207

Delaware  
(State or other jurisdiction  
of incorporation)

33-0728374  
(IRS Employer  
Identification No.)

2929 Seventh Street, Suite 100  
Berkeley, CA 94710-2753  
(Address of principal executive offices, including zip code)

(510) 848-5100  
(Registrant's telephone number, including area code)

(Former name or former address, if changed since last report)

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
- 
-

**Item 2.02. Results of Operations and Financial Condition**

On November 5, 2015, Dynavax Technologies Corporation ("Dynavax") issued a press release announcing its financial results for the quarter ended September 30, 2015. A copy of the press release is attached as Exhibit 99.1 to this current report and is incorporated herein by reference.

The information with respect to item 2.02 in this current report and its accompanying exhibit shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in this current report and in the accompanying exhibit shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by Dynavax, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

**Item 9.01. Financial Statements and Exhibits**

(d) Exhibits. The following exhibit is furnished herewith:

99.1 Press Release, dated November 5, 2015, titled "Dynavax Reports Third Quarter 2015 Financial Results"

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dynavax Technologies Corporation

Date: November 5, 2015

By: /s/ DAVID JOHNSON  
David Johnson  
Vice President

---

**EXHIBIT INDEX**

<b>Exhibit No.</b>	<b>Description</b>
EX-99.1	Press Release, dated November 5, 2015, titled "Dynavax Reports Third Quarter 2015 Financial Results"

# DYNAVAX

INNOVATING IMMUNOLOGY

2929 Seventh Street, Suite 100  
Berkeley, CA 94710

**Contact:**

Michael Ostrach  
Chief Financial Officer  
510-665-7257  
mostrach@dynavax.com

## DYNAVAX REPORTS THIRD QUARTER 2015 FINANCIAL RESULTS

BERKELEY, CA – November 5, 2015 – Dynavax Technologies Corporation (NASDAQ: DVAX) today reported financial results for the third quarter ended September 30, 2015.

The Company had \$220.7 million in cash, cash equivalents and marketable securities as of September 30, 2015, compared to \$93.4 million at June 30, 2015. The balance at September 30, 2015 includes approximately \$164 million of net proceeds from sales of common stock in the third quarter and reflects payment of all principal and accrued interest, prepayment charges and other fees totaling approximately \$11 million under a loan agreement.

Operating expenses of \$29.6 million for the quarter ended September 30, 2015 increased by \$4.8 million compared to the quarter ended June 30, 2015 primarily due to production, clinical trial and commercial preparation costs.

We recently initiated a clinical trial to evaluate the combination of our cancer immunotherapeutic product candidate SD-101 and Merck's KEYTRUDA® (pembrolizumab) in patients with metastatic melanoma. All study visits for HBV-23, the Phase 3 clinical study of HEPLISAV-B™, were completed in October 2015. Top line results of this study are expected to be released in early 2016.

The net loss allocable to common stockholders for the quarter ended September 30, 2015 was \$30.1 million, or \$0.82 per basic and diluted share. The net loss allocable to common stockholders for the quarter ended June 30, 2015 was \$23.6 million, or \$0.80 per basic and diluted share.

### About Dynavax

Dynavax, a clinical-stage biopharmaceutical company, uses TLR biology to discover and develop novel vaccines and therapeutics in the areas of infectious and inflammatory diseases and oncology. Dynavax's lead product candidates are HEPLISAV-B, a Phase 3 investigational adult hepatitis B vaccine, and SD-101, an investigational cancer immunotherapeutic currently in several Phase 1/2 studies. For more information visit [www.dynavax.com](http://www.dynavax.com).

---

## Forward Looking Statements

This release contains forward-looking statements, including statements regarding expected timing of results from HBV-23. These statements are subject to a number of risks and uncertainties that could cause actual results to differ materially, including whether HBV-23 can be completed as expected, whether the endpoints of the study will be achieved and the final results otherwise be satisfactory, whether successful development and approval of HEPLISAV-B and our process for its manufacture can occur in a timely manner or without significant additional studies or difficulties or delays; whether clinical studies for our products can be enrolled, supplied and completed in a timely manner and will be sufficient for further development or for marketing approval; the potential size and value of approved indications addressable with HEPLISAV-B and the commercial potential for HEPLISAV-B; initiation and completion of pre-clinical studies and clinical trials of our other product candidates; the results of clinical trials and the impact of those results on the initiation or continuation of subsequent trials and issues arising in the regulatory process; achieving the objectives of and maintaining our collaborative and licensing agreements; our ability to execute on our commercial strategies; whether our financial resources will be adequate without the need to obtain additional financing and other risks detailed in the "Risk Factors" section of our most recent current periodic report filed with the SEC. These statements represent our estimates and assumptions only as of the date of this presentation. We do not undertake any obligation to update publicly any such forward-looking statements, even if new information becomes available.

– tables to follow –

---

**DYNAVAX TECHNOLOGIES CORPORATION**  
**CONSOLIDATED STATEMENTS OF OPERATIONS**  
(In thousands, except per share amounts)  
(Unaudited)

	<b>Three Months Ended</b>		<b>Nine Months Ended</b>	
	<b>September 30,</b>		<b>September 30,</b>	
	<u>2015</u>	<u>2014</u>	<u>2015</u>	<u>2014</u>
Revenues:				
Collaboration revenue	\$ 829	\$ 1,795	\$ 2,230	\$ 6,199
Grant revenue	359	414	608	2,546
Service and license revenue	-	-	527	10
Total revenues	1,188	2,209	3,365	8,755
Operating expenses:				
Research and development	24,105	28,072	66,011	64,942
General and administrative	5,524	4,083	15,481	12,325
Unoccupied facility expense	-	131	-	386
Total operating expenses	<u>29,629</u>	<u>32,286</u>	<u>81,492</u>	<u>77,653</u>
Loss from operations	(28,441)	(30,077)	(78,127)	(68,898)
Interest income	33	42	78	162
Interest expense	(62)	-	(572)	-
Other income, net	17	216	360	300
Loss on extinguishment of debt	(1,671)	-	(1,671)	-
Net loss	<u>\$ (30,124)</u>	<u>\$ (29,819)</u>	<u>\$ (79,932)</u>	<u>\$ (68,436)</u>
Basic and diluted net loss per share	<u>\$ (0.82)</u>	<u>\$ (1.13)</u>	<u>\$ (2.43)</u>	<u>\$ (2.60)</u>
Shares used to compute basic and diluted net loss per share	<u>36,532</u>	<u>26,291</u>	<u>32,880</u>	<u>26,288</u>

**DYNAVAX TECHNOLOGIES CORPORATION**  
**SELECTED BALANCE SHEET DATA**  
(In thousands)

	<u>September 30,</u> <u>2015</u>	<u>December 31,</u> <u>2014</u>
	<u>(unaudited)</u>	
<b>Assets</b>		
Cash, cash equivalents and marketable securities	\$ 220,697	\$ 122,652
Property and equipment, net	11,606	7,924
Goodwill	2,106	2,277
Other assets	<u>4,498</u>	<u>5,437</u>
Total assets	<u>\$ 238,907</u>	<u>\$ 138,290</u>
<b>Liabilities and stockholders' equity</b>		
Deferred revenues	\$ 10,546	\$ 12,765
Other liabilities	17,173	15,484
Long-term debt	-	<u>9,559</u>
Total liabilities	27,719	37,808
Stockholders' equity	<u>211,188</u>	<u>100,482</u>
Total liabilities and stockholders' equity	<u>\$ 238,907</u>	<u>\$ 138,290</u>

###